Inhomogeneous Localization of Radioactivity in the Human Kidney After Injection of [111In-DTPA]Octreotide

Journal of Nuclear Medicine

Axel Bex¹  Jean-Claude Reubi¹  Roelf Valkema¹  Eric P. Krenning¹  Eric Pieter van de Weyer¹  Meike Körner¹  Jan Dirk Burggraaf¹  Arthur van Gameren¹  Hester van Boven¹  Marion de Jong¹ 

关键词: radionuclide therapy;    radiopharmaceuticals;    renal;    kidney;    octreotide;    peptide receptor radionuclide therapy;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

In peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with β-emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and retention of the radionuclides after glomerular filtration. Dosimetry calculations are mostly based on the MIRD scheme, assuming homogeneous renal radioactivity distribution. The aim of this study was to reveal the radioactivity distribution in the normal human kidney after intravenous injection of [111In-diethylenetriaminepentaacetic acid (DTPA)]octreotide. Methods: Three patients received intravenous injection of [111In-DTPA]octreotide before nephrectomy because of renal cancer. Distribution of radioactivity in the human kidney was investigated using SPECT scanning before and ex vivo autoradiography of the kidney after surgery. Results: Radioactivity was localized predominantly in the cortex of the kidney. In the cortex, radioactivity was not distributed homogeneously but formed a striped pattern, with most of the radioactivity centered in the inner cortical zone. Conclusion: These findings show that average dose calculations using the MIRD scheme, assuming homogeneous renal radioactivity distribution, are inadequate to estimate the radiation dose to various parts of the kidney after PRRT. Different effects due to inhomogeneity can be expected from PRRT using radionuclides emitting particles with short particle ranges, for example, Auger electron emitters, α-emitters, and low-energy β-emitters.

【 授权许可】

Unknown